Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

78P - Association between obesity, sex, and overall survival in patients with metastatic cancers treated with first- or second-line immune checkpoint inhibitors

Date

10 Sep 2022

Session

Poster session 01

Topics

Population Risk Factor;  Cancer Treatment in Patients with Comorbidities;  Immunotherapy

Tumour Site

Renal Cell Cancer;  Melanoma;  Non-Small Cell Lung Cancer

Presenters

Mingjia Li

Citation

Annals of Oncology (2022) 33 (suppl_7): S27-S54. 10.1016/annonc/annonc1037

Authors

M. Li1, S. Zhao2, J. Guo3, M. Husain1, J. Schafer4, K. Chakravarthy4, G. Lopez1, D. Spakowicz1, L. Wei2, E. Bertino1, A. Alahmadi1, R. Memmott1, J. Kaufman1, K. He1, C. Presley1, P. Shields1, D.P. Carbone1, G.A. Otterson1, D.H. Owen1

Author affiliations

  • 1 Internal Medicine Department, The Ohio State University - OSU Wexner Medical Center, 43210 - Columbus/US
  • 2 Biomedical Informatics, OSUCCC - The Ohio State University Comprehensive Cancer Center - James, 43210 - Columbus/US
  • 3 College Of Pharmacy, OSUCCC - The Ohio State University Comprehensive Cancer Center - James, 43210 - Columbus/US
  • 4 Medical Oncology, OSUCCC - The Ohio State University Comprehensive Cancer Center - James, 43210 - Columbus/US
More

Abstract 78P

Background

Obesity exerts a wide arrange of physiological effects on health. Aside from its influences on oncogenesis, its impact on cancer outcomes is not completely understood. Adipose tissue is known to play a critical role in androgen and estrogen metabolism, and recent evidence established a link between male sex and T-cell exhaustion, both of which may affect the responsiveness of the immune system to immunotherapy. Here, we explored the relationship between body mass index (BMI), sex, and overall survival in patients (pts) with metastatic cancers treated with immune checkpoint inhibitors (ICIs).

Methods

We retrospectively studied pts with metastatic cancers treated with first or second-line ICI between 2011-2017 at Ohio State University. Pre-treatment BMI was collected. Cox proportional hazards models were used to assess the association between variables. Effect modification by sex was assessed using an interaction term. Analyses were performed in SAS 9.4.

Results

There was 688 pts included in our study. 403 (58.6%) were males and 285 (41.4%) were females. 286 (41.6%) had EOCG performance status 0, 283 (41.1%) had ECOG 1, 107 (15.5%) had ECOG ≥2, 12 (1.7%) had unknown ECOG. 360 (52.3%) received first-line ICI-based therapies and 328 (47.7%) received as second-line. The top 3 cancer types were: 277 (40.3%) melanoma, 157 (22.8%) non-small cell lung cancer, 67 (9.7%) renal cell carcinoma. Median BMI was 28.0 with interquartile range 23.9-32.4. For every unit increased in BMI, risk of death was decreased by 1.8% (HR=0.982 with 95% CI 0.969-0.995, p=0.007) in the overall cohort. However, the associations of BMI with death were different in male VS female (interaction p= 0.003). In male pts, for 1 unit increased in BMI, the hazard of death decreased by 3.6 % (HR=0.964 with 95 % CI 0.946 - 0.982, p<0.001); Among female pts, there was reversed but not significant association (HR=1.003 with 95% CI 0.985-1.022, p=0.726). In multivariate analysis, BMI was a significant prognostic factor for survival after adjusting for ECOG, line of therapy, and cancer types in male pts only.

Conclusions

High BMI in male, but not female, was associated with improved overall survival in pts with metastatic cancers treated with ICIs.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.